1Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus[7]. Arthritis Rheum, 1982,25: 1271-1277.
6Cathcart ES, Idelson BA. Beneficial effects of methyprednisolone "pulse" therapy in diffuse proliferative lupus nephritis[J]. Lancet, 1976, 7: 163-166.
7Edwards JC, Snaith ML. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualized outcome assessment[J] .Ann Rheum Dis, 1987, 46(10): 773-776.
8Austin Ⅲ HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs[J] .N Eng J Med, 1986, 314: 614-619.
9Goldman L eds. Cecil Textbook of Medicine[M]. philadelphia: Saunders, 2004.1660-1670.
4Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic' lupus erythematosus. A prospective cohort study. Arthritis Rheum, 1991, 34: 937-944.
5ter Borg EJ, Horst G, Hummel EJ, et ah Measurement of increases in anti-double-stranded DNA antibody levels as a prcdietor of disease exacerbation in systemic lupus erythematosus. A long-term.prospective study. Arthritis Rheum, 1990. 33: 634-643.
6Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.1982, 25: 1271-1277.
7Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640.
8Livneh A, Or G, Many A, et al. Anti-DNA antibodies secreted by peripheral B cells of lupus patients have hoth normal and lupusspecific features. Clin Immunol Immunopathol. 1993.68: 68-73.
9Miret C, Font J, Molina R, et al. Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity. Anticancer Res, 1999, 19: 3073-3076.
10Jodo S, Kobayashi S, Kayagaki N, el al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.Clin Exp Immunol, 1997, 107: 89-95.
